Estrogen receptor (ER) a plays an important role in the proliferation and progression of breast cancer. In order to explore the function of wild-type ERb (ERb1) and its variant form, ERbcx/b2, stable transformants of ERapositive breast cancer MCF7 cells with ERb1 or ERbcx/ b2 expression vector were established. Constitutive expression of ERb1 or ERbcx/b2 reduced the S phase population of the cell cycle in dish culture and the number of colonies in an anchorage-independent assay. DNAprotein complexes of ERE with nuclear extracts from ERb1 transformants were observed in the electrophoretic mobility shift assay, while no complex was observed for ERbcx/b2 transformants. Reporter gene assay using estrogen-responsive element (ERE)-luciferase showed less responsiveness to estrogen in these transformants compared with parental cells. Endogenous mRNA expression of two known estrogen-responsive genes, cathepsin D and IGFBP4, was weakly induced by estrogen in ERb1 and ERbcx/b2 transformants compared with parental cells. A comprehensive gene expression analysis using our custommade cDNA microarray showed that MCF7 and ERb1 transformants had a similar gene expression profile, whereas ERbcx/b2 showed a distinct profile from others. These results indicate that ERb1 and ERbcx/b2 inhibit ERa function differently in MCF7 cells.
Introduction
Estrogen plays an important role not only in the development of normal mammary glands but also in the proliferation and progression of breast cancer. The estrogen signal is mediated by the estrogen receptor (ER), which is a transcription factor belonging to the steroid hormone receptor superfamily. The second ER, ERb, was identified in 1996 (Kuiper et al., 1996; Ogawa et al., 1998) , and since then the former ER has been called ERa. Clinically, the expression of ERa is the most effective predictor of hormone therapy responsiveness in breast cancer (Early Breast Cancer Trialists' Collaborative Group, 1998; Locker, 1998) . However, ERa is not a perfect predictor of hormone therapy: only about 70% of ERa-positive patients respond to the therapy while 10% of ERa-negative ones also respond (NIH Consensus Development Conference, 1980) . Therefore, many studies have been performed to seek additional or alternative predictive factors.
Since ERb was shown to be expressed in breast cancer (Enmark et al., 1997) , a number of studies have been performed to determine whether ERb is such a predictor (Dotzlaw et al., 1997; Leygue et al., 1998; Speirs et al., 1999; Vladusic et al., 2000) . Meanwhile, various ERb isoforms generated by alternative splicing were reported in addition to the wild-type ERb (ERb1) (Moore et al., 1998; Ogawa et al., 1998; Vladusic et al., 1998) . Specific detection of ERb1 from other variants could indicate the significance of ERb1 expression in breast cancer: ERa-positive ones showed higher expression levels of ERb1 than negative ones, indicating that ERb1 was a good prognostic factor (Jarvinen et al., 2000; Omoto et al., 2001a Omoto et al., , 2002 . Alternative splicing of exons encoding the carboxy terminal portions generates ERbcx (Ogawa et al., 1998) , also called ERb2 (Moore et al., 1998) (ERbcx/b2) , and the other splicing variants, ERb3, ERb4, and ERb5 (Moore et al., 1998) . Among them, ERbcx/b2 is identical to ERb1 except that the last exon 8 is replaced by 26 unique amino-acid residues. The mRNA expression of ERbcx/b2 was observed to be higher than ERb1 in human breast cancer (Iwao et al., 2000; Tong et al., 2002) , indicating that this variant might have a specific function in breast cancer. However, the clinical implication of ERbcx/b2 has not been made clear yet. ERbcx/b2 expression has also been investigated in other endocrine-related cancers, such as those of the prostate (Fujimura et al., 2001 ) and ovary (Chu et al., 2000) . Fujimura et al. (2001) indicated that high ERbcx/b2 expression was correlated with poor prognosis in prostate cancer.
The binding affinity of ERb1 to 17b-estradiol (E2) was approximately half that of ERa (Hall and McDonnell 1999) ; ERb1 showed less potent transcriptional activity on estrogen-responsive element (ERE) than ERa did (Cowley and Parker 1999). ERb1 can form a homodimer or a heterodimer with ERa, and both of these dimers bound to ERE and showed estrogendependent ERE transcriptional activity in vitro (Pettersson et al., 1997) . On the other hand, another variant, ERbcx/b2, lacked binding activity to E2 (Ogawa et al., 1998; Peng et al., 2003) . Additionally, it showed no DNA binding ability (Ogawa et al., 1998) or much less than ERb1 (Moore et al., 1998; Peng et al., 2003) , although ERbcx/b2 inhibited the binding of ERa to ERE (Ogawa et al., 1998) . These data suggest that ERbcx/b2 may act as a dominant-negative regulator of ERa in the breast.
Many clinical investigations suggested that ERb1 and/or ERbcx/b2 might be expressed in ERa-positive breast cancer at the same time. It is necessary to investigate the function of ERb1 and/or ERbcx/b2 coexpressing with ERa to understand estrogen-mediated carcinogenesis in the breast.
Very recently, we reported that the expression of ERbcx/b2 influences the expression of the progesterone receptor (PgR), and ERbcx/b2 may be an alternative and useful prognostic factor for evaluating ERa-positive breast cancer using preoperative needle biopsies (Saji et al., 2002) . This prompted us to conduct mechanistic analyses of ERbcx/b2 function in ERa-positive breast cancer.
In the present study, we established stable transformants of ERa-positive breast cancer MCF7 cells with ERb isoform expression vectors to investigate the function of ERb isoforms in combination with ERa.
Results

Establishment of MCF7 cells expressing ERb1 or ERbcx/b2
In order to explore the function of ERb isoforms in ERa-positive human breast cancer cells, transformants of MCF7 cells constitutively expressing ERb1 or ERbcx/b2 were established. We isolated more than 10 clones from each of these transformants. Several clones were isolated from mock-transfected MCF7 in parallel, and two of them, named CMV#1 and CMV#3, were used for further study. RT-PCR was performed to select several clones expressing high levels of ERb1 (Figure 1a) or ERbcx/b2 mRNA (Figure 1b) . Then, we analysed the protein levels of ERb1 or ERbcx/b2 by Western blotting among these clones (Figure 1c ). The specificity of this antibody was confirmed with in vitro synthesized protein of ERb1 and ERbcx (Figure 1c ). Two clones of each transformant were selected for further studies: b1#1 and b1#2, or bcx#1 and bcx#2, with higher ERb1 or ERbcx/ b2 expression than the other clones and parental MCF7 cells. The expression levels of ERa protein were comparable among these transformants and parental cells (Figure 1d ). We also confirmed the protein expression of ERs by immunohistochemical methods. Positive staining of transfected ERb1 or ERbcx/b2 as well as endogenous ERa was observed in these transformants. On the other hand, in parental MCF7, CMV#1 and CMV#3 cells showed no staining with ERb antibody (Figure 1e, CMV#3 ; data not shown), whereas they showed positive ERa staining.
Effects of ERb1 or ERbcx/b2 expression on cell growth
In order to evaluate the effects of constitutive expression of ERb1 and ERbcx/b2 on cell growth, we performed Expression of ERb1 or ERbcx/b2 in isolated clones was analysed by RT-PCR. The mRNA from Cos-7 cells was used as negative control. ERb1 or ERbcx/b2 transiently transfected Cos-7 cells were used as positive control. PCR products of ERb1 amplification (274 bp) were separated on a 1% agarose gel (a). ERbcx/b2 and ERb5 amplification products (214 and 295 bp, respectively) were separated on 6% polyacrylamide gels containing 7 m urea (b). The primer set for ERbcx/b2 detection would also recognize one ERb isoform, ERb5, producing a ERb5 amplification band at the same time. For each sample, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified (142 bp) in parallel, and separated on a 1% agarose gel (a, b). M, DNA marker; n.c., control PCR without cDNA. (c) ERb1 or ERbcx/b2 protein detection by Western blotting using anti-ERb rabbit polyclonal antibody (Upstate). Cell lysates from Cos7 cells were used as negative control. The protein synthesized by in vitro transcription translation (TNT) was used to confirm the antibody specificity. 
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Y Omoto et al cell-cycle analysis and an anchorage-independent colony formation assay. Five days of estrogen depletion induced G0-G1 arrest in cell-cycle analysis; more than 80% of the cells were in the G0-G1 phase in parental MCF-7 cells, and all mock, ERb1 or ERbcx/b2 stable transformants (data not shown). On the other hand, about 40% of MCF7, CMV#1 and CMV#3 cells entered the S phase in the exponential growth condition with 10% FCS; however, only about 30% of ERb1 or ERbcx/b2 transformants entered the S phase (Figure 2a) , suggesting that the exponential growth ability of these stable transformants was less than parental MCF7 cells.
In the anchorage-independent colony formation assay, the parental MCF-7, CMV#1 and CMVx3 cells could form colonies even without E2, and showed an increased number of colonies with the addition of E2. However, the transformants constitutively expressing ERb1 or ERbcx/b2 showed no colony formation in the absence of E2, and only a small number of colonies appeared in the presence of E2 (Figure 2b, CMV#3 ; data not shown). Although the number of colonies in bcx#2 was slightly higher than the other transformants, the size of colonies in this cell was smaller than the others, and colony formation was still very much lower than parental cells. These data indicate that ERb1 and ERbcx/b2 stable transformants have less anchorage-independent growth ability than parental MCF7 cells, although estrogen stimulated the growth of not only parental MCF7 cells but also ERb1 or ERbcx/b2 stable transformants.
DNA binding activity of ERb isoforms
ERbcx/b2 has been reported to possess no or less binding activity with ERE than ERb1 (Moore et al., 1998; Ogawa et al., 1998; Peng et al., 2003) . Therefore, we investigated the binding activity of ERb1 or ERbcx/ b2 expressed in the transformants to ERE. Nuclear extracts of MCF7 cells and mock-transfected transformants CMV#1 and CMV#3 formed two complexes with labeled ERE, and they were blocked by excess amounts of cold ERE probe but not by nonspecific competitors (Figure 3a , CMV#1 and CMV#3; data not shown). Nuclear extracts from b1#1 and b1#2 formed three complexes, all of which were blocked by cold ERE probe but not by nonspecific competitors (Figure 3b, b1#2 ; data not shown). Two complexes that migrated more slowly were observed for b1#1 cells and MCF7 cells. Another complex that migrated faster than the others was also present for b1#1 cell; this may be due to the formation of ERb1 homodimer. On the other hand, nuclear extracts from bcx#1 and bcx#2 cells formed no complexes (Figure 3c , bcx#2; data not shown). These data indicate that ERb1 and ERbcx/b2 interact differently with ERa to alter its ERE binding activity.
Effects of ERb1 or ERbcx/b2 expression on ERE transcriptional activity
Next, we investigated the effects of constitutive expression of ERb1 or ERbcx/b2 on the transcriptional activity through ERE, using pERE-tk-Luc reporter plasmid. The parental MCF7, CMV#1 and CMV#3 cells showed about 25-fold enhanced transcriptional activity by addition of E2 (Figure 4 ). On the other hand, b1#1, b1#2, bcx#1 and bcx#2 cells showed only 3-4-fold enhanced transcriptional activity with E2 additives (Figure 4 ). These data suggest that ERb1 and ERbcx/ b2 stable transformants possess less potent activity on ERE than parental MCF7 cells.
Effects of ERb1 or ERbcx/b2 expression on regulation of estrogen target genes
To clarify whether there was any difference in the regulation of target genes by E2 among parental MCF7 cells, ERb1 and ERbcx/b2 transformants, we assessed the mRNA expression of two well-known estrogenresponsive genes, cathepsin D and IGFBP4, by Northern blotting (Figure 5a ). The expression levels of these two genes were measured and standardized by that of b-actin. Cathepsin D was induced about 2-3-fold in parental MCF7, CMV#1 and CMV#3 cells, but, only about 1-1.5-fold in ERb1 and ERbcx/b2 stable transformants (Figure 5b ). In the case of IGFBP4, its induction level was more apparent: 3-4 fold induction in parental MCF7, CMV#1, and CMV#3 cells; 1-1.5-fold in ERb and ERbcx stable transformants ( Figure 5c ). On the other hand, estrogen-independent MCF7-ADR cells (Vickers et al., 1988) showed no E2 responsiveness. 
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Assessment of target genes responding to estrogen using cDNA microarray
In order to find differences between ERb1 and ERbcx/ b2 transformants in terms of target gene regulation by estrogen, we performed cDNA microarray analysis using our custom-made microarray . This array was specialized for the assessment of estrogen-responsive genes, especially regulated in MCF7 cells. A total of 148 cDNA fragments of estrogenresponsive genes were inoculated, including cathepsin D and IGFBP4. All cells were treated for 72 h with or without E2 in order to observe the gene expression profiles of breast cancer at the steady-state level, which may reflect the net estradiol effects on the cells.
The results of the microarray analysis are shown in Figure 6 . In MCF7 and CMV#1 cells, about two-thirds of the genes were upregulated (red) and one-third were downregulated (green) by estrogen. b1#1 and b1#2 cells showed very similar patterns of gene expression to MCF7: the number of differently expressed genes among these cells was less than 10. On the other hand, bcx#1 showed a different color pattern; around 16 genes were clustered as the downregulated group in MCF7 and unchanged or upregulated in bcx#1 cells; around 12 genes were upregulated in MCF7 and unchanged or downregulated in bcx#1 cells. The names of the genes in these clusters are shown in Figure 6 .
A tree diagram of each cell showed that the gene expression profiles of MCF7 and CMVx1 cells were very similar to each other. In addition, b1#1 and b1#2 cells were in a group very close to that for MCF7 and CMV#1 cells. On the other hand, the gene expression profile of bcx#1 was unique in that it differed not only from MCF7 and ERb1 transformants but also from ERa-negative MCF7-ADR cells showing no responsiveness to estrogen. The transcriptional activity through ERE in ERb1 or ERbcx/b2 stable transformants of MCF7. After 5 days of culture in PRF-RPMI with 10% DCC-FCS, 1 Â 10 5 cells were plated on 3.5 cm diameter plastic culture plates in the same medium and incubated for 24 h. The cells were cotransfected with 1 mg of pERE-tk-Luc and 0.1 mg of pRL-TK plasmid, and cultured for a further 24 h in the presence of ethanol vehicle or increasing concentrations of E2 (1, 10 and 100 nm). Luciferase activity was measured in triplicate and normalized with pRL-TK activity. Columns, means; bars, s.d.
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Discussion
ERb has a number of variants generated by alternative splicing. Among them, ERbcx/b2 has been highlighted as possessing a dominant-negative effect on ERa function. Very recently, we found that the expression of ERbcx/b2 may provide an alternative and useful prognostic factor for evaluating ERa-positive breast cancer using preoperative needle biopsies (Saji et al., 2002) , warranting mechanistic analyses of ERbcx/b2 function in ERa-positive breast cancer. Among several estrogen-dependent ERa-positive breast cancer cell lines, MCF7 is one of the most frequently used cells for functional observation of estrogen response. Therefore, we used MCF7 cells and established transformants stably expressing ERb1 or ERbcx/b2 to investigate the function of ERb1 or ERbcx/b2 in the presence of ERa. Cell-cycle analysis showed that the S phase population was much smaller in ERb1 and ERbcx/b2 transformants than parental MCF7 cells. Additionally, the number of colonies was reduced in both ERb1 and ERbcx/b2 transformants compared with parental cells in the anchorage-independent colony formation assay. These data suggested that both ERb1 and ERbcx/b2 have inhibitory functions in breast cancer cell growth modulated by estrogen. Lazennec et al. (2001) reported that ERb1 inhibited cell motility and invasion to a greater degree than ERa. In our Figure 6 Gene expression profile of ERb1 and ERbcx/b2 transformants of MCF-7 using the custom-made cDNA array. After 2 days of culture in PRF-RPMI medium with 10% DCC-FCS, the cells were incubated for a further 3 days in the presence of 10 nm of E2 or ethanol vehicle. The mRNA from E2-depleted cells was labeled with Cy5-dUTP and the mRNA from E2-added cells was labeled with Cy3-dUTP. Hybridization signal intensities were measured, quantified and normalized as described previously . Differential expression levels are shown as the average log 2 calibrated ratio of Cy3 to Cy5. Hierarchical cluster analysis was carried out, and the results were displayed with the 'TreeView' software. All the names of these genes will be supplied upon request
showed morphological changes such as a more rounded shape, and they were tightly attached to each other and resistant to trypsin treatment, whereas CMV#1 and CMV#3 cells were the same as MCF7 cells (data not shown). It seemed that the cell adhesion condition had changed in these transformants and might reflect not only cell proliferation but also the potential of cell motility and invasion in ERb1 and ERbcx/b2 transformants.
Subsequently, we investigated ERs-ERE complex formation by electrophoretic mobility shift assay (EMSA). A previous in vitro study showed that ERb1 could bind to ERE as its homodimer as well as heterodimer with ERa (Pettersson et al., 1997) . On the contrary, ERbcx/b2 had no (Ogawa et al., 1998) or less (Moore et al., 1998; Peng et al., 2003) binding activity to ERE. Our data showed that the nuclear extracts from MCF7 cells formed two complexes, which were presumably ERa homodimer and heterodimer of ERa and ERb1. An additional, faster migrating band was observed for nuclear extracts from ERb transformants: overexpression of ERb1 may be required to form its homodimer. On the other hand, no complex was observed when nuclear extracts from ERbcx/b2 transformants were analysed. Our data indicated that ERbcx/ b2 had no binding ability, although ERb1 could bind to ERE as a homodimer or heterodimer with ERa. Additionally, ERbcx/b2 inhibit ERa binding to ERE. Our data were consistent with the report of Ogawa et al. (1998) . We used nuclear extracts from ERbcx/b2 transfected cultured cells as did Ogawa et al. (1998) , although Moore et al. (1998) and Peng et al. (2003) used synthesized protein by in vitro transcription/translation. This difference could have influenced the DNA binding ability. In any case, these data clearly suggested that both ERb1 and ERbcx/b2 could interact with ERa and may influence ERE-mediated transcriptional activity. An interesting point is that these two ERb isoforms have been shown to interact differently with ERa. ERb1 competed for ERa in binding to ERE; ERb1 formed a homodimer or heterodimer with ERa. On the other hand, ERbcx/b2 inhibited ERa binding with ERE by still unknown mechanisms. This may require further mechanistic analysis to reveal the role of ERbcx/b2 in the regulation of ERa function.
The transcriptional activity of ERs was investigated using pERE-tk-Luc vector, and revealed that EREmediated transcription activity was remarkably reduced in ERb1 and ERbcx/b2 transformants compared with parental MCF7 cells in response to estrogen. These data indicated that ERb1 and ERbcx/b2 have some negative effects on inducing ERE transcriptional activity. The change in the ERs-ERE complex in these transformants would influence the transcriptional activity of ERE.
The expressions of two well-established estrogen target genes, namely cathepsin D and IGFBP4, were assessed to evaluate the regulation of gene expression by E2 in these transformants. The expression levels of these genes were reduced in estrogen-depleted conditions, while clear induction by estrogen was observed in parental MCF7 cells. In addition, the induction ratio of both genes was lower in ERb1 or ERbcx/b2 transformants than in MCF7 cells. Cathepsin D is known as an estrogen-responsive gene in breast cancer cell lines (Rochefort et al., 1987) . It has been shown to stimulate tumor growth (Berchem et al., 2002) , and overexpression of this gene correlated with poor prognosis in breast cancer (Rochefort, 1992; Ferrandina et al., 1997; Foekens et al., 1999) . IGFBP4, a protein mediating the growth of cells, is known as an E2-responsive gene (Owens et al., 1993; Pratt and Pollak 1993) , and correlated with the ERa status in primary breast cancer (Clemmons et al., 1990; Figueroa et al., 1993) . Thus, the downregulation of proliferation-related genes including cathepsin D and IGFBP4 might provide the growth inhibitory effects of ERb1 and ERbcx/b2 transformants.
Different downstream gene regulation between ERb1 and ERbcx/b2 was observed in cDNA microarray experiments ( Figure 6 ). Although there are a number of ERb variants, no consideration has been given to these species differences with respect to the regulation of genes by E2. cDNA microarray is one of the most efficient tools for the comprehensive analysis of gene expression. The custom microarray we used here is specialized to assess the ERa-mediated estrogen-responsive genes, especially in MCF7 cells ; that is most arrayed genes were regulated through ERa. Actually, an interesting difference in the gene expression profile between ERb1 and ERbcx/b2 transformants was observed with this specialized tool ( Figure 6 ). The gene expression profiles of ERb1 transformants in the presence of E2 showed very similar patterns to that of MCF7, although the degree of change in the gene expression was slightly weaker in ERb1 transformants than in MCF7 by addition of E2. On the other hand, the gene expression profiles of ERbcx transformants were distinct from that of MCF7; about 16 genes were clustered as downregulated in MCF7 and unchanged or upregulated in ERbcx/b2 transformants, and about 12 genes were clustered as upregulated in MCF7 and unchanged or downregulated in ERbcx/b2 transformants. These results indicate that ERb1 and ERbcx/b2 have different specificities in regulating gene promoters.
The two genes we performed Northern blotting on were included in this microarray. The cluster including IGFBP4 was distinguished as estrogen upregulated genes. Its regulation was upregulated in MCF7 and CMV#1 cells, whereas almost no change was observed in b1#1, b1#2 and bcx#1 cells (Figure 6 ). Cathepsin D was characterized into a unique cluster in the microarray, but there was not such a dramatic difference among these cells ( Figure 6 ); they were slightly downregulated in bcx#1 but upregulated in the others. The gene expression we observed in Northern blotting was almost reproducible and was consistent with that in this microarray. The individual gene data from the microarray was shown as the ratio without consideration of its expression level; therefore, this method would be more suitable for recognizing the gene expression profile.
There have been some reports on different gene regulation between ERa and ERb1. Lazennec et al. (2001) introduced ERa and ERb1 expression plasmids into an estrogen-independent ER-negative breast cancer cell line, MDA-MB-231, and suggested that regulation of pS2, TGF-a and p21 genes by E2 was mediated by both ERa and ERb1, while that of the c-myc gene was mediated by only ERa. Bie`che et al. (2001) investigated the gene expression in breast cancer samples, and suggested that PgR and pS2 were mainly regulated by ERa, while cyclinD1 was mainly regulated by ERb1 in sporadic breast cancer. Among these genes, pS2 was included in our microarray, and was basically upregulated by estrogen, but was higher in MCF7 and bcx#1 than b1#1 and b1#2, and seemed to be regulated mainly by ERa, without stimulation of ERE transcription. These three experimental backgrounds were all different from each other, and would therefore result in different observations in independent cases. Concerning the expression level between ERa and ERb, a higher level of ERb would be possible in this in vitro model than in vivo. The ratio of ERa and ERb protein present in vivo is still not clear, and it could vary among individual cases. This kind of model study would not be applicable to all situations in vivo; however, accumulation of knowledge should provide the different roles of ERa, ERb1 and ERbcx/b2.
Some of the genes were differentially upregulated or downregulated in bcx#1 cells. It is possible that the expression of individual genes reflected the difference in cell growth ability, because all cells were treated for 72 h with or without E2. bcx#1 showed a clearly different profile from MCF7, unlike b1#1 and b1#2, which showed a sort of 'weakened' gene expression pattern of MCF7. This indicated that ERbcx/b2 not only inhibits ERa by direct and/or indirect interaction, but possibly has some active role. Interestingly, ERa was downregulated in MCF7, b1#1 and b1#2, whereas it was upregulated in bcx#1 cells by estrogen in this microarray study. This suggested that ERa did not function even if there was a ligand in bcx#1 and would provide a different profile of hormonal responsiveness in ERapositive breast cancer.
Another interesting point was that many estrogenresponsive genes were regulated by E2 in ERbcx/b2 transformants, even though nuclear extracts of the cells showed no ERE binding complex. On the other hand, there was no regulation of estrogen-responsive genes in ERa-negative MCF7-ADR cells. This suggested that ERbcx/b2 interacts with ERa to inhibit its binding to ERE; however, the effect of E2 administration still remained in ERbcx/b2 transformants. For example, the hormone-dependent cell growth was not mediated by only ERE-mediated transcription. ERs could also indirectly bind to AP-1 or Sp-1 sites and activate the transcriptional activities in addition to the classical nuclear signaling pathway (Paech et al., 1997) . Furthermore, it has also been reported that the membrane or cytosolic ER is involved in the rapid cell growth signaling pathway through MAP kinase (Russell et al., 2000) . Taken together, the genes we identified here as being differently regulated by estrogen between ERb1 and ERbcx/b2 transformants may provide a clue to uncovering a novel function of ERbcx/b2, when breast cancer cells grow under an estrogen-dependent condition.
In conclusion, our study demonstrated that both ERb1 and ERbcx/b2 had different inhibitory effects on ERa-mediated cell growth and regulation of target genes. The altered gene expression profiles suggested that these two isoforms might differently affect breast cancer biology in terms of estrogen responsiveness.
Materials and methods
Cells and culture
The human breast cancer cell line resistant to adriamycin, MCF7-ADR, was kindly provided by Dr M Toi (Tokyo Metropolitan Komagome Hospital, Tokyo, Japan) (Btist et al., 1986; Toi et al., 1992) . This cell was derived from MCF7, but showed ERa-negative and estrogen-independent cell growth (Vickers et al., 1988) . Human breast cancer cell lines MCF7 and MCF7-ADR were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), and simianderived Cos-7 cells were cultured in RPMI 1640 with 5% FCS, at 371C in a humidified atmosphere of 5% CO 2 in air. All culture media contained 2 mm l-glutamine, 5 U/ml penicillin and 5 mg/ml streptomycin (Sigma, Tokyo, Japan). For experiments to evaluate the effect of E2, phenol red-free RPMI 1640 (PRF-RPMI) and dextran-coated charcoal-treated FCS (DCC-FCS) were substituted for RPMI 1640 and FCS, respectively.
Plasmids
The ERb1 expression vector pRc/CMV-ERb was previously described (Omoto et al., 2001b) . The ERbcx/b2 expression vector pRc/CMV-ERbcx was constructed by recombination of the exon 8 sequence of pRc/CMV-ERb with the ERbcx/b2 sequence. The construction of these plasmids was confirmed by sequencing with an ABI PRISM 310 genetic analyzer (PerkinElmer, Foster City, CA, USA).
The estrogen-responsive reporter plasmid pERE-tk-Luc was described previously (Omoto et al., 2001b) . The control vector pRL-TK (Promega, Madison, WI, USA) was used as an internal control of transfection efficiency in a reporter assay.
Stable transfection
MCF-7 cells were transfected with pRc/CMV-ERb or pRc/ CMV-ERbcx, using TransIT LT-1 reagent (Takara) according to the manufacturer's instructions. After 1 day of culture, the cells were grown in fresh RPMI 1640 supplemented with 10% FCS containing 1 mg/ml of geneticin (G418) (Sigma) for another 10 days. Isolated colonies were trypsinized in metal ring cups, and the cells were further cultured in the presence of 200 mg/ml G418.
RNA extraction and reverse transcriptase-polymerase chain reaction (RT-PCR)
RNA extraction was performed using TRIZOL reagent (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. Reverse transcription was performed as previously described (Omoto et al., 2000) . Briefly, 1 mg of total RNA was reverse transcribed using random primers and M-MLV reverse transcriptase (Gibco BRL, Rockville, MD, USA). In total, 1 ml of synthesized cDNA was subjected to PCR amplification using Taq polymerase (Takara). The PCR conditions for ERs were described previously . Briefly, detection of ERb1 and ERbcx/2 was performed according to the method of Leygue et al. (1999) , with a slight modification. Primers located at the 3 0 -terminus consisting of ERU (5 0 -CGA TGC TTT GGT TTG GGT GAT-3 0 ; sense, in exon 7) and ERL1 (5 0 -GCC CTC TTT GCT TTT ACT GT-3 0 ; antisense, in exon 8) are for ERb1 mRNA amplification. ERU and ERL2 (5 0 -CTT TAG GCC ACC GAG TTG ATT-3 0 ; antisense, consensus sequence in ERbcx/b2 and ERb5) primers are for ERbcx mRNA amplification. This primer set amplified another splicing variant, ERb5, at the same time. Each reaction consisted of 30 cycles (30 s at 941C, 30 s at 601C and 30 s at 721C). The PCR products were separated on a 1% agarose gel or 6% polyacrylamide gels containing 7 m urea, and visualized by ethidium bromide staining under ultraviolet (UV) illumination. The housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was used as a control, as previously described (Eguchi et al., 2000) . Briefly, oligonucleotides used in PCR amplification were 5 0 -ACA TCG CTC AGA CAC CAT GG-3 0 and 5 0 -GTA GTT GAG GTC AAT GAA GGG-3 0 . The PCR reaction consisted of 24 cycles and its products were separated on a 1% agarose gel.
Immunoblotting
Western blot analysis was performed as previously described (Omoto et al., 2001b) . Briefly, aliquots of 50 mg of cell extracts were subjected to 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and proteins were electrically transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA), and incubated with primary anti-ERa rabbit polyclonal antibody G-20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1/2000 dilution, or anti-ERb rabbit polyclonal antibody (Upstate Biotechnology, Lake Placid, NY, USA) at 1/500 dilution. The secondary antibody was AP-conjugated anti-rabbit antibody (Bio-Rad Laboratories, Hercules, CA, USA) at 1/3000 dilution. Detection of ERa and ERb was performed using Immun-Star Substrate (Bio-Rad) and a Fuji Luminoimage Analyzer LAS-1000 system (Fuji Film, Tokyo, Japan) . To confirm the specificity of ERb antibody to both ERb1 and ERbcx/b2, we synthesized both proteins by in vitro transcription translation using pRc/CMV-ERb and pRc/CMV-ERbcx expression vectors and TNT Coupled Reticulocyte Lysate Systems (Promega, Madison, WI, USA). Cell lysates from Cos7 cells were used as negative control.
Immunohistochemical staining
The cells were cultured in a culture dish with a cover glass in the bottom. The cells growing on the cover glass were fixed with 4% paraformaldehyde for 20 min at room temperature and washed with phosphate-buffered saline (PBS). The fixed cells were then treated with 0.5% Triton-X containing PBS (PBST) for 10 min to make them permeable. After washing with PBS, Block-Ace solution (Dai-nippon Pharmaceutical, Osaka, Japan) was applied for 10 min for blocking. These samples were incubated overnight at 41C with the primary anti-ERa mouse monoclonal antibody 1D-5 (Dako, Glostrup, Denmark) at 1/100 dilution, or the anti-ERb mouse monoclonal antibody ERb-14C8 (GeneTex, San Antonio, TX, USA) at 1/200 dilution. After washing with PBST, Cy3-conjugated goat anti-mouse antibody was applied for 45 min at room temperature. The staining of these cells was observed by fluorescence microscopy.
Assessment of cell cycle
The cell-cycle analysis procedure was previously described (Honma et al., 1999) . Briefly, after 5 days of culture in PRF-RPMI with 10% DCC-FCS or RPMI with 10% FCS, the cells had grown to less than 60% confluency, and were then washed in ice-cold PBS, fixed by the addition of 70% ethanol and left for 30 min on ice. The cell pellet was washed and suspended in 100 ml of 1.12% sodium citrate containing RNase A (250 mg/ml) for 30 min at 371C. Thereafter, the cells were stained with 100 mg/ml of propidium iodide in the presence of 1.12% sodium citrate and analysed on an Epics EX flow cytometer (Coulter Electronics, Fullerton, CA, USA) in duplicate.
Anchorage-independent colony formation assay
After 5 days of culture in PRF-RPMI medium with 10% DCC-FCS, 2 Â 10 4 cells were suspended in 1.5 ml of 0.33% Difco's noble agar in PRF-RPMI with 10% DCC-FCS in the presence of the indicated additives and layered over 4 ml of 0.66% agar-medium basal layer in triplicate in 6 cm diameter plastic culture plates. The cells were then fed with PRF-RPMI medium with DCC-FCS in the presence of the indicated additives and incubated for 21 days with the medium being changed every 3 days. The number of colonies per dish larger than 50 mm in diameter was then counted in triplicate.
Electrophoretic mobility shift assay
EMSA was performed essentially as described previously (Tanimoto et al., 1999) . Briefly, double-stranded oligonucleotides containing a vitellogenin ERE were labeled with [a-32 P]dCTP using the Klenow fragment of DNA polymerase I (Takara, Tokyo, Japan). Nuclear extracts of each cell, which were cultured in RPMI 1640 medium supplemented with 10% FCS, were prepared using a CelLytic Nuclear Extraction Kit (Sigma), and stored at À1501C until use. A measure of 20 mg of nuclear extracts was incubated with increasing amounts (20-200 ng) of nonlabeled competitor ERE, nonspecific competitor AP-1 (120 ng) and Sp-1 (120 ng), as indicated. A measure of 2 ng of radiolabeled ERE probe (10 4 c.p.m.) was added to the reaction mixture and incubated on ice for 20 min. The reaction mixture was then separated on a 5% polyacrylamide gel running for 3.5 h at 41C in 0.5 Â Tris/borate/EDTA (TBE) buffer.
Luciferase assays
Transient transfection was performed essentially as described previously (Omoto et al., 2001b ) with a slight modification. Briefly, after 5 days of culture in PRF-RPMI with 10% DCC-FCS, 1 Â 10 5 cells were plated on 3.5 cm diameter plastic culture plates in the same medium and incubated for 24 h. In all, 1 mg of pERE-tk-Luc plasmid and 0.1 mg of pRL-TK were mixed with 5 ml of TransIT LT-1 reagent (Takara) in 100 ml of serum-free medium and subjected to transfection according to the manufacturer's instructions. After culturing the cells for a further 24 h in the presence of 1, 10 or 100 nm of E2, or ethanol vehicle, the cells were lysed in 1 Â Passive Lysis buffer and reporter gene activities were measured in triplicate using a Dual Luciferase Assay System (Promega, Madison, WI, USA).
Northern blotting
After 2 days of culture in PRF-RPMI medium with 10% DCC-FCS, the cells were incubated for a further 3 days in the presence of ethanol or 10 nm of E2. The Northern blotting procedure was previously described . Briefly, 20 mg of total RNA was electrophoresed and transferred to a Hybond N membrane (Amersham Pharmacia Biotech). DNA fragments used for hybridization probes were prepared by RT-PCR using total RNA from MCF-7 cells as a template. The oligonucleotide sequences for cathepsin D amplification were 5 0 -CGC TCG CCC TCT GCC TGC T-3 0 and 5 0 -GGC TGC GAT GAA GGT GAT GC-3 0 (557 bp). Those for insulin-like growth factor binding protein 4 (IGFBP4) and b-actin were described in a previous paper . A total of 25 ng of cDNA fragments was labeled with [a-32 P]dCTP using Megaprime TM DNA labeling systems (Amersham Pharmacia Biotech), and hybridization was carried out using ExpressHyb TM Hybridization Solution (Clontech) according to the manufacturer's instructions. The hybridization band intensity was measured by a Fuji BioImage Analyzer FLA-3000 (Fuji film, Tokyo, Japan) and normalized with b-actin expression.
Custom-made cDNA microarray analysis
The microarray technique used in this study was described in our previous paper in detail. Briefly, 148 genes that were regulated by estrogen in ERa-positive breast cancer cell lines using large-scale microarray were selected and inoculated onto this custom microarray. After 2 days of culture in PRF-RPMI medium with 10% DCC-FCS, the cells were incubated for a further 3 days in the presence of 10 nm of E2 or ethanol vehicle. The mRNA was extracted from these cells using a PolyATtract system 1000 (Promega), according to the manufacturer's instructions. In all, 2 mg of mRNA from E2-depleted cells and E2-treated cells was labeled with Cy5-dUTP and Cy3-dUTP (Amersham Pharmacia Biotech), respectively. Cy3-and Cy5-labeled probes were mixed together in 2 Â SSC/ 0.2% SDS, and applied to a microarray slide under a coverslip. Hybridization was conducted overnight at 651C in a humidified hybridization chamber. Hybridization signals were measured using ChipReader (Virtek, Ontario, Canada) according to the manufacturer's instructions.
Custom microarray data analysis
Signal intensities were quantified and normalized using IPLab (Scanalytics, Fairfax, VA, USA) as described previously . Differential expression levels were shown as the average log 2 calibrated ratio of Cy3 to Cy5. Hierarchical cluster analysis (average linkage clustering using a Pearson correlation as a similarity metric) was carried out using the 'Cluster' software program, and the results were displayed with the 'TreeView' software program developed by Eisen et al. (1998) .
